Osteoarthritis Clinical Trial Pipeline Advances As 100+ Companies Develop 110+ Novel Therapies Across All Clinical Stages, Finds Delveinsight Biosplice Therapeutics, Regeneron Pharmaceuticals

(MENAFN- GetNews)


"Osteoarthritis – Pipeline Insight, 2026"The leading Osteoarthritis companies include Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, LG Chem, ICM Biotech, UnicoCell Biomed, Magellan Biologicals, Levicept, ZYUS Life Sciences, Lubris Biopharma, Saol Therapeutics, Ageless Biotech, Synartro AB, Plakous Therapeutics, Ribomic, Meluha Therapeutics and others.

DelveInsight's "Osteoarthritis – Pipeline Insight, 2026" report provides comprehensive insights about 100+ companies developing 110+ pipeline drugs in the Osteoarthritis pipeline landscape. It covers the Osteoarthritis pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Osteoarthritis treatment landscape. Learn more about the evolving Osteoarthritis pipeline today @

Key Takeaways from the Osteoarthritis Pipeline Report

• On March 23, 2026, Enlivex received authorization from the FDA to proceed with its investigational new drug application (IND) for Allocetra, an immunotherapy for moderate-to-severe age-related symptomatic primary knee osteoarthritis. This clearance enables the company to initiate a comprehensive, global, randomized, double-blind, placebo-controlled Phase 2b clinical trial.

• Lorecivivint (SM04690), developed by Biosplice Therapeutics, represents the most advanced pipeline candidate for Osteoarthritis, currently under evaluation in a Phase III clinical trial as a potential disease-modifying osteoarthritis drug (DMOAD), targeting Wnt and inflammatory pathways with a dual mechanism of action.

• 4P004, a GLP-1 analog developed by 4P-Pharma, is being evaluated in a Phase II clinical trial as a potential first-in-class disease modifier drug for Osteoarthritis (DMOAD), demonstrating anti-inflammatory, anti-catabolic, and anabolic properties.

• GNSC-001, a gene therapy candidate developed by Genascence, is currently in Phase I clinical evaluation for Osteoarthritis, offering a novel single-injection approach designed to provide long-term, sustained inhibition of interleukin-1 (IL-1) by expressing an optimized form of IL-1Ra via a recombinant adeno-associated viral vector.

• DelveInsight's Osteoarthritis Pipeline Insight report depicts a robust and highly active space with 100+ companies working to develop 110+ pipeline therapies for Osteoarthritis treatment.

• The leading Osteoarthritis companies include Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, LG Chem, ICM Biotech, Cells for Cells SA, GWOXI Stem Cell Applied Technology, UnicoCell Biomed, Magellan Biologicals, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Orient Europharma, ZYUS Life Sciences, Lubris Biopharma, Saol Therapeutics, Ageless Biotech, Synartro AB, Plakous Therapeutics, Ribomic, Meluha Therapeutics and others.

• Promising Osteoarthritis therapies include Lorecivivint, EP-104IAR, DFV890, 4P004, GNSC-001 and others.

Download for updates and the latest revolution in Osteoarthritis care @ Osteoarthritis Clinical Trials Assessment

Osteoarthritis Emerging Drugs Profile

• Lorecivivint: Biosplice Therapeutics

Lorecivivint (SM04690) is a small-molecule CLK/DYRK1A inhibitor that modulates Wnt and inflammatory pathways and is in development as a potential disease-modifying osteoarthritis drug (DMOAD). Vehicle-controlled preclinical data suggest that lorecivivint has a dual mechanism of action with three potential effects on joint health: reduction of inflammation, slowing of cartilage breakdown, and generation of cartilage. The drug is currently in Phase III stage of clinical trial evaluation to treat patients suffering from osteoarthritis.

• EP-104IAR: Eupraxia Pharmaceuticals

EP-104IAR is Eupraxia Pharmaceuticals' lead product candidate, designed to meet the significant unmet medical need and market demand for long-lasting disease relief in multiple indications benefitting from highly localized and longer delivery of corticosteroids, with the lead indication being pain relief in knee osteoarthritis. EP-104IAR encapsulates a highly potent corticosteroid (fluticasone propionate) within a microns-thin polymer membrane as part of Eupraxia's patented technology platform. When injected into the knee, EP-104IAR is designed to diffuse the corticosteroid slowly into the knee joint, providing local therapeutic concentrations for up to six months - offering a potential dual advantage of longer duration of pain relief with fewer systemic side effects. Currently, the drug is in Phase II stage of its clinical trial for the treatment of OA.

For more information on the Osteoarthritis Emerging Drugs Profile, download DelveInsight's comprehensive Osteoarthritis Pipeline Insight report.

The Osteoarthritis Pipeline Report Provides

• Detailed insights about companies developing therapies for Osteoarthritis, with aggregate therapies developed by each company.

• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Osteoarthritis treatment.

• Osteoarthritis companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Osteoarthritis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company–company and company–academia), licensing agreements, and financing details for future advancement of the Osteoarthritis market.

Learn more about Osteoarthritis Drugs opportunities in our comprehensive Osteoarthritis pipeline report @ Osteoarthritis Unmet Needs

Osteoarthritis Companies

There are 100+ key companies, such as Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, LG Chem, ICM Biotech, Cells for Cells SA, GWOXI Stem Cell Applied Technology, UnicoCell Biomed, Magellan Biologicals, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Orient Europharma, ZYUS Life Sciences, Lubris Biopharma, Saol Therapeutics, Ageless Biotech, Synartro AB, Plakous Therapeutics, Ribomic, Meluha Therapeutics and others, developing therapies for Osteoarthritis, with Biosplice Therapeutics having its Osteoarthritis drug candidate in the most advanced Phase III stage.

DelveInsight's Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Osteoarthritis products have been categorized under various Molecule types such as:

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Discover the latest advancements in Osteoarthritis treatment by visiting our website. Stay informed @ Osteoarthritis Market Drivers and Barriers, and Future Perspectives

Scope of the Osteoarthritis Pipeline Report

• Coverage: Global

• Osteoarthritis companies: Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, LG Chem, ICM Biotech, Cells for Cells SA, GWOXI Stem Cell Applied Technology, UnicoCell Biomed, Magellan Biologicals, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Orient Europharma, ZYUS Life Sciences, Lubris Biopharma, Saol Therapeutics, Ageless Biotech, Synartro AB, Plakous Therapeutics, Ribomic, Meluha Therapeutics and others

• Osteoarthritis Therapies: Lorecivivint, EP-104IAR, DFV890, 4P004, GNSC-001 and others.

• Osteoarthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Osteoarthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Table of Contents

1. Introduction

2. Executive Summary

3. Osteoarthritis: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Osteoarthritis – DelveInsight's Analytical Perspective

7. Late Stage Products (Phase III)

8. Mid Stage Products (Phase II)

9. Early Stage Products (Phase I)

10. Preclinical and Discovery Stage Products

11. Inactive Products

12. Osteoarthritis Key Companies

13. Osteoarthritis Key Products

14. Osteoarthritis Unmet Needs

15. Osteoarthritis Market Drivers and Barriers

16. Osteoarthritis Future Perspectives and Conclusion

17. Osteoarthritis Analyst Views

18. Appendix

MENAFN25032026003238003268ID1110907794